# Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

> **NCT00026208** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 76 (actual)

## Conditions studied

- Lymphoma, Hodgkin Disease
- Lymphoma
- Hodgkin Disease
- Lymphoma: Hodgkin

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Bleomycin
- **DRUG:** Etoposide
- **RADIATION:** Low-dose radiotherapy (RT)

## Key facts

- **NCT ID:** NCT00026208
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2013-04-26
- **Final completion:** 2017-02-13
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00026208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00026208, "Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00026208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*